Lung Cancer 2006, 52:155–163.PubMedCrossRef 20. Belani CP, Waterhouse H, Ghazal H, et al.: Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer Linsitinib (NSCLC). J Clin Oncol 2010,28(15s):abstr 7506. 21. Perol M, Chouaid C, Milleron J, et al.: Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy
in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010,28(15s):abstr 7507. 22. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM: Multicenter, randomized trial for stage IIIB or IV non small cell lung cancer using weekly paclitaxel or observation. J Clin Oncol 2003, 21:2933–2939.PubMedCrossRef 23. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727–17233.PubMed 24. Coate LE, Shepherd FA: Maintenance therapy in advanced
non small cell lung cancer. JTO 2010,5(5):723–734. 25. Westeel V, Quoix E, Moro Sibilot D, Mercier M, Breton JL, Debieuvre D, Richard Dichloromethane dehalogenase P, Haller MA, Milleron B, Herman D, Level MC, Puyraveau M, Depierre
A: Randomized study of maintenance vinorelbine in responders with advanced PD0332991 cell line non-small cell lung cancer. J Natl Cancer Inst 2005, 97:499–506.PubMedCrossRef 26. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Kazmierski MH, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH: Phase III study of immediate versus delayed docetaxel after front line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2009, 27:591–8.PubMedCrossRef 27. Ciuleanu T, Brodowicz T, Zielinski C Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira J, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Tariquidar mw Krejcy K, Belani CP: Maintenance pemetrexed plus best supportive care vesus placebo plus best supportive care for non-small cell lung cancer: a randomized double-blind, phase III study. Lancet 2009, 374:1432–4.PubMedCrossRef 28. Scagliotti GV, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology, a review of two phase III studies. Oncologist 2009, 14:253–63.PubMedCrossRef 29.